Muhammed Erdem Ercan

Muhammed Erdem Ercan

Auto-generated profile, based on publicly available information

Muhammed Erdem Ercan

Koc University Research Center for Translational Medicine (KUTTAM)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in FEBS Open Bio
Verified
Journal Article
Open access
AAAbed Alkarem Abu Alhaija
Abed Alkarem Abu Alhaija
ILImtiaz Lone
Imtiaz Lone
ESEsin Ozkuru Sekeroglu
Esin Ozkuru Sekeroglu
TBTugce Batur
Tugce Batur
DADimitar Angelov
Dimitar Angelov
Kasim DirilKasim Diril
Kasim Diril
The linker histone H1 C‐terminal domain (CTD) plays a pivotal role in chromatin condensation. De novo frameshift mutations within the CTD coding region of H1.4 have recently been reported to be associated with Rahman syndrome, a neurological disease that causes intellectual disability and overgrowth. To investigate the mechanisms and pathogenesis of Rahman syndrome, we developed a cellular model using murine embryonic stem cells (mESCs) and CRISPR/Cas9 genome engineering. Our engineered mES cells facilitate detailed investigations, such as H1‐4 dynamics, immunoprecipitation, and nuclear localization; in addition, we tagged the mutant H1‐4 with a photoactivatable GFP (PA‐GFP) and an HA tag to facilitate pulldown assays. We anticipate that these engineered cells could also be used for the development of a mouse model to study the in vivo role of the H1‐4 protein.

10 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EKEzgi Yagmur Kala
Ezgi Yagmur Kala
FAFiliz Senbabaoglu Aksu
Filiz Senbabaoglu Aksu
EEErdem Ercan
Erdem Ercan
AOAltar Ozbiyik
Altar Ozbiyik
ACAhmet Cingoz
Ahmet Cingoz
TBTugba Bagci-Onder
Tugba Bagci-Onder
Temozolomide (TMZ) remains the standard of care for glioblastoma; however, its efficacy is frequently influenced by epigenetic mechanisms, notably the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter. While MGMT promoter hypermethylation is associated with enhanced responsiveness to TMZ, additional epigenetic determinants of TMZ resistance remain largely undefined. In this study, we established TMZ-resistant glioblastoma cell lines that consistently maintained their resistant phenotype both in vitro and in vivo . Transcriptomic analyses revealed a marked upregulation of MGMT expression in these models. To systematically investigate the epigenetic regulators governing TMZ resistance and cell survival, we conducted CRISPR/Cas9-based functional genomic screens using our focused Epigenetic Knock-Out Library (EPIKOL), which targets 800 chromatin regulators alongside selected positive and negative controls. These unbiased screens validated MGMT as a primary mediator of TMZ resistance, confirming the robustness of our approach. Moreover, dropout screens across multiple resistant cell line models identified Retinoblastoma Binding Protein 4 (RBBP4) as a critical vulnerability. Notably, RBBP4 knockout significantly impaired cell proliferation without affecting MGMT expression, suggesting a distinct mechanism supporting the survival of TMZ-resistant glioblastoma cells. Subsequent transcriptomic profiling following RBBP4 loss demonstrated significant downregulation of cell cycle pathways, particularly the G2/M checkpoint. Live-cell imaging and immunofluorescence analyses further revealed increased cell size and multinucleation in RBBP4-deficient cells, indicative of disrupted mitotic progression. Collectively, our results identify RBBP4 as a key regulator of cell cycle progression and survival in TMZ-resistant glioblastoma and highlight its potential as a novel epigenetic target for therapeutic intervention in recurrent disease.